After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

BioSpace

Hello, and welcome to BioSpace Weekly. I'm your host, Jeff Axt. The biggest news from this past week is that Replimune finally crossed the regulatory finish line, earning FDA approval for its twice-rejected therapy for advanced melanoma, so that was some good news. Last week also saw the last of the major pharmas report second-quarter earnings. These included obesity giants Eli Lilly and Novo Nordisk, so we will recap those for you.

And finally, psychedelics made headlines once again as Frontrunners Compass Pathways and Diffinium Therapeutics provided updates on near-term catalysts for their psilocybin and LSD-based candidates. Let's get started. Hi, guys. Good to see you. Welcome back. Hi, Jeff. Yeah, thank you for being back. I am done with travel for the foreseeable future. I am home, hopefully forever. You're not allowed going away on earnings again, but I do hope you had a good time.

I did. It was a family wedding, and my kids just danced the night away with other little cousins. It was a blast. So, yeah, you guys had a busy week last week with earnings, and then Replimune, you guys sent out a breaking email. I saw those texts come and go. I was busy with family stuff. We were glad you ignored them. Heather was on it. She had, you know, the story ready, and then she just had to slot in which way it was going to go. So, it was good news.

It was really unclear which way it was going to go. We'll get into that in just a minute, but usually we, like, we know it's probably going to be approved or probably going to be rejected, and we just write the one pre-write. This time, it was really a crapshoot. Yeah, yeah.

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.